Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Canada Jetlines Announces $13.5 Million Equity Financing (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biovaxys Technology Corp C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology. In addition, the Company is developing its CoviDTH, a diagnostic for evaluating the presence or absence of a T... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:BIOV)

BioVaxys and The Ohio State University Extend Research Collaboration

PR Newswire August 29, 2023

An out-of-favour biotech stock developing next-gen cancer vaccines

Trevor Abes  August 25, 2023

BIOVAXYS ANNOUNCES MANAGEMENT CHANGE

Canada NewsWire June 30, 2023

BioVaxys Announces Sale of TAET Software Co

Newsfile June 14, 2023

BIOVAXYS REPORTS AGM RESULTS

Canada NewsWire June 7, 2023

BioVaxys Technology (CSE:BIOV) retains Maxim Group as financial advisor and investment banker

Trevor Abes  April 18, 2023

BIOVAXYS RETAINS MAXIM GROUP AS FINANCIAL ADVISOR AND INVESTMENT BANKER

PR Newswire April 17, 2023

BIOVAXYS ANNOUNCES APPOINTMENT OF CFO AND BOARD CHANGES

PR Newswire April 12, 2023

BioVaxys (CSE:BIOV) acquires TAETSoftware, completes financing

Trevor Abes  March 16, 2023
View More News ››

Opinion & Analysis (CSE:BIOV)

Unique Value-Added Antiviral Vaccine Technology Platform

Dave Jackson September 15, 2021
View More Opinion ››

Bullboard Posts (CSE:BIOV)

RE:RE:Things are coming together, just cleaning the market.

Great potentiality here; the volume is now over 2 million . All we need now is some positive news and away we go into a home run to the...
Appreciation777 - August 30, 2023

RE:Things are coming together, just cleaning the market.

I agree, IMO things did slow down but this is expected with the kind of work ( research, failure, trial and error etc,). Hopefully, we...
mba123ccu - August 29, 2023

Things are coming together, just cleaning the market.

As it was pointed out the volume could double tomorrow as things are coming together on some new development. Best of Luck; we could be a...
Appreciation777 - August 29, 2023

BIOV OUR SLEEPING GIANT HAS AWAKEN$$ GREAT DAY! over 1.4 MIL

but also some shannigans goings on TD & ANON..hmmm  Recent Trades - Last 10 of 70 More trades... ...
moneywagon - August 29, 2023

An out-of-favour biotech stock developing next-gen vaccines

https://stockhouse.com/news/newswire/2023/08/25/an-out-favour-biotech-stock-developing-next-gen-cancer-vaccines
TrevorAbes - August 25, 2023

RE:Roll it back 1 for 20

Great potentiality here for BIOV, once they roll it back. They may not have to do 1 for 20 as there is 105 Million outstanding only ...
Appreciation777 - July 28, 2023
View more Bullboard ››

Hank Payments Corp.

Hank Payments Corp.

Hank Payments is a North American leader in consumer Fintech Software-as-a-Service (“SaaS”) in the Banking-as-a-Service ...
View More »